Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
NCT ID: NCT04143217
Last Updated: 2024-02-13
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Total Enrollment
159 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-01-23
Study Completion Date
2022-12-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 in adult ADHD patients
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
NCT04016779
Attention-Deficit/Hyperactivity Disorder (ADHD)
COMPLETED
PHASE3
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
NCT02736656
Attention-Deficit/Hyperactivity Disorder
ACTIVE_NOT_RECRUITING
PHASE3
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
NCT04781140
Attention-Deficit/Hyperactivity Disorder
RECRUITING
PHASE4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
NCT03247517
ADHD
COMPLETED
PHASE3
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
NCT03247530
ADHD
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a multicenter, open-label extension study aimed to assess long-term safety and efficacy of SPN-812 when administered alone or in conjunction with an Food and Drug Administration (FDA)-approved Attention-Deficit Hyperactivity Disorder (ADHD) medication in the treatment of ADHD in adult subjects who completed a blinded study of SPN-812 (812P306). Subjects initiate SPN-812 dosing at 200 mg/day once daily (QD) during first 2 weeks. At or after Visit 2 (Week 2), per the Investigator's discretion and based on Investigator's assessment of subject's clinical response and tolerability, the dose of SPN-812 can be titrated up or tapered down in increments of 50 mg/day, 100 mg/day, 150 mg/day, or 200 mg/day per week to a target dose within the ranges between 200 and 600 mg/day. Additionally, after 12 weeks of dosing (after Visit 4), at the discretion of the Investigator and based on subject's clinical response, the optimized dose of SPN-812 may be supplemented with an adjunctive FDA-approved stimulant treatment. Total treatment duration per subject from Visit 1 to Visit 22 (end of study) is approximately 3 years (156 weeks ± 1 week) or until SPN-812 becomes commercially available.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Attention-Deficit/Hyperactivity Disorder
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Single Group Assignment
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
None (Open Label)
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Open-Label Treatment
SPN-812 Open-Label Treatment 200mg to 600mg SPN-812 once daily for up to 156 weeks
Group Type
EXPERIMENTAL
SPN-812
Intervention Type
DRUG
SPN-812 200 to 600 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SPN-812
SPN-812 200 to 600 mg/day
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
viloxazine extended-release capsules (Qelbree)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Is a male or female who completed Study 812P306 and opts/consents to participate in the study if approved by PI.
2. Continues to be medically healthy and with clinically normal laboratory profiles, vital signs, and electrocardiograms (ECGs), in the opinion of the Investigator, assessed at Visit 1.
3. Is able to read and understand the Informed Consent Form (ICF).
4. Has signed the ICF.
5. Is willing and able to attend study appointments within specified time windows.
6. Is a female of childbearing potential (FOCP) who is either sexually inactive (abstinent) or, if sexually active, agrees to use one of the following acceptable birth control methods beginning at least 30 days prior to the first dose of SM and throughout the study:
1. Simultaneous use of male condom and intra-uterine contraceptive device placed at least 4 weeks prior to first SM administration
2. Surgically sterile male partner
3. Simultaneous use of male condom and diaphragm with spermicide
4. Established hormonal contraceptive
Females are considered not to be of childbearing potential if they are either post-menopausal (amenorrhea for at least 2 years and serum follicle stimulating hormone \[FSH\] level of \>40 IU/L) or permanently sterilized (e.g., bilateral tubal ligation, hysterectomy, bilateral oophorectomy for 6 months minimum prior to their Visit 1).
7. Is a male who:
1. Agrees to use 2 methods of contraception in combination if his female partner is of childbearing potential; this combination of contraceptive methods must be used from Visit 1 to ≥ 1 month after the last dose of SM, OR
2. Has been surgically sterilized prior to Visit 1.
1. Is male or female, aged 18 to ≤ 65 years at screening.
2. Is able to read and understand the Informed Consent Form (ICF).
3. Written informed consent obtained from the subject (a signed ICF).
4. Weight within the normal or overweight ranges according to accepted values of the Body Mass Index (BMI) Chart (18.0 to 35.0 kg/m2).
5. Is able to swallow capsules whole, without crushing, chewing or cutting.
6. Is willing and able to attend study appointments within the specified time windows.
7. Has a primary diagnosis of ADHD according to the DSM-5 classification, with diagnosis made at least 6 months prior to screening and confirmed with Structured Clinical Interview for DSM-5 Clinical Trials version (SCID-5-CT; de novo subjects).
8. Has an AISRS total score of ≥ 24 at the screening (Visit 'S').
9. Has a CGI-S score of ≥ 4 (mildly ill or worse) at the screening (Visit 'S').
10. Females of childbearing potential (FOCP) must be either sexually inactive (abstinent) or, if sexually active, must agree to use one of the following acceptable birth control methods beginning at least 28 days prior to the first dose of SM and throughout the study:
1. Simultaneous use of male condom and intra-uterine contraceptive device placed at least 4 weeks prior to first SM administration
2. Surgically sterile male partner
3. Simultaneous use of male condom and diaphragm with spermicide
4. Established hormonal contraceptive
Females are considered not to be of childbearing potential if they are either postmenopausal (amenorrhea for at least 2 years and serum follicle stimulating hormone \[FSH\] level of \>40 IU/L) or permanently sterilized (e.g., bilateral tubal ligation, hysterectomy, bilateral oophorectomy for 6 months minimum prior to screening).
11. Males must:
1. Use 2 methods of contraception in combination if his female partner is of childbearing potential; this combination of contraceptive methods must be used from Visit 1 (baseline) to ≥ 1 month after the last dose of SM; or
2. Have been surgically sterilized prior to the Screening Visit.
2. Continues to be medically healthy and with clinically normal laboratory profiles, vital signs, and electrocardiograms (ECGs), in the opinion of the Investigator, assessed at Visit 1.
3. Is able to read and understand the Informed Consent Form (ICF).
4. Has signed the ICF.
5. Is willing and able to attend study appointments within specified time windows.
6. Is a female of childbearing potential (FOCP) who is either sexually inactive (abstinent) or, if sexually active, agrees to use one of the following acceptable birth control methods beginning at least 30 days prior to the first dose of SM and throughout the study:
1. Simultaneous use of male condom and intra-uterine contraceptive device placed at least 4 weeks prior to first SM administration
2. Surgically sterile male partner
3. Simultaneous use of male condom and diaphragm with spermicide
4. Established hormonal contraceptive
Females are considered not to be of childbearing potential if they are either post-menopausal (amenorrhea for at least 2 years and serum follicle stimulating hormone \[FSH\] level of \>40 IU/L) or permanently sterilized (e.g., bilateral tubal ligation, hysterectomy, bilateral oophorectomy for 6 months minimum prior to their Visit 1).
7. Is a male who:
1. Agrees to use 2 methods of contraception in combination if his female partner is of childbearing potential; this combination of contraceptive methods must be used from Visit 1 to ≥ 1 month after the last dose of SM, OR
2. Has been surgically sterilized prior to Visit 1.
1. Is male or female, aged 18 to ≤ 65 years at screening.
2. Is able to read and understand the Informed Consent Form (ICF).
3. Written informed consent obtained from the subject (a signed ICF).
4. Weight within the normal or overweight ranges according to accepted values of the Body Mass Index (BMI) Chart (18.0 to 35.0 kg/m2).
5. Is able to swallow capsules whole, without crushing, chewing or cutting.
6. Is willing and able to attend study appointments within the specified time windows.
7. Has a primary diagnosis of ADHD according to the DSM-5 classification, with diagnosis made at least 6 months prior to screening and confirmed with Structured Clinical Interview for DSM-5 Clinical Trials version (SCID-5-CT; de novo subjects).
8. Has an AISRS total score of ≥ 24 at the screening (Visit 'S').
9. Has a CGI-S score of ≥ 4 (mildly ill or worse) at the screening (Visit 'S').
10. Females of childbearing potential (FOCP) must be either sexually inactive (abstinent) or, if sexually active, must agree to use one of the following acceptable birth control methods beginning at least 28 days prior to the first dose of SM and throughout the study:
1. Simultaneous use of male condom and intra-uterine contraceptive device placed at least 4 weeks prior to first SM administration
2. Surgically sterile male partner
3. Simultaneous use of male condom and diaphragm with spermicide
4. Established hormonal contraceptive
Females are considered not to be of childbearing potential if they are either postmenopausal (amenorrhea for at least 2 years and serum follicle stimulating hormone \[FSH\] level of \>40 IU/L) or permanently sterilized (e.g., bilateral tubal ligation, hysterectomy, bilateral oophorectomy for 6 months minimum prior to screening).
11. Males must:
1. Use 2 methods of contraception in combination if his female partner is of childbearing potential; this combination of contraceptive methods must be used from Visit 1 (baseline) to ≥ 1 month after the last dose of SM; or
2. Have been surgically sterilized prior to the Screening Visit.
Exclusion Criteria
1. Is currently participating in another clinical trial other than Study 812P306.
2. Has any current psychiatric disorder per Diagnostic and Statistical Manual of Mental Disorders - 5th Edition (DSM-5) criteria other than ADHD with the following exceptions: ADHD is primary diagnosis with comorbidity/secondary diagnoses of major depression disorder (MDD), nicotine dependence, social anxiety disorder, generalized anxiety disorder, or phobias.
3. Current diagnosis of significant systemic disease and/or of a major psychiatric or neurological disorder, including history or family history of seizures or seizure-like disorders.
4. Current evidence of suicidality (suicidal thoughts or behaviors).
5. Female subjects who are pregnant, lactating and/or sexually active and not agreeing to use one of the acceptable birth control methods throughout the study.
6. Has a positive result on urine drug screen at Visit 1.
7. Use of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) at the Visit 1 for the duration of the study.
8. Has a clinical laboratory value, vital sign value or ECG result at Visit 1 that is considered to be clinically significant in the opinion of the Investigator.
9. Has one or more clinical laboratory test values outside the reference range at Visit 1 that, in the opinion of the Investigator, are clinically significant, or any of the following (see Note below):
* Serum creatinine \> 1.5 times the upper limit of normal (ULN);
* Serum total bilirubin \> 1.5 times ULN;
* Serum alanine aminotransferase or aspartate aminotransferase \> 2 times ULN.
10. Has any of the following cardiology findings at Visit 1 (see Note below):
* Abnormal ECG that is, in the Investigator's opinion, clinically significant;
* PR interval \> 220 ms;
* QRS interval \> 130 ms;
* QTcF interval \> 450 ms (for men) or \> 470 ms (for women) (QT corrected using Fridericia's method);
* Second- or third-degree atrioventricular block;
* Any rhythm, other than sinus rhythm, that is interpreted by the Investigator to be clinically significant.
11. Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
1. Is currently participating in another clinical trial or has participated in a clinical trial within 60 days prior screening, with the exception of Study 812P306.
2. Is a member of the study personnel or of their immediate families, or is a subordinate (or immediate family member of a subordinate) to any of the study personnel.
3. Female subjects who are pregnant, lactating and/or sexually active and not agreeing to use one of the acceptable birth control methods throughout the study.
4. Has a history of severe drug allergy or hypersensitivity, or known hypersensitivity, to the study medication.
5. Has a history of moderate or severe head trauma or other neurological disorder or systemic medical disease that, in the Investigator's opinion, is likely to affect central nervous system functioning. This would include subjects with:
1. A current diagnosis of a major neurological disorder; or
2. Seizures, seizure disorder or seizure-like events; or a history of seizure disorder within the immediate family (siblings, parents); or Encephalopathy
6. Has any history of schizophrenia, schizoaffective disorder, bipolar disorder, borderline personality disorder, antisocial personality disorder, narcissistic personality disorder, autism, post-traumatic stress disorder or obsessive-compulsive disorder.
7. Has any current psychiatric disorder (per DSM-5 criteria) other than ADHD with the following exceptions: ADHD is primary diagnoses with comorbidity/secondary diagnoses of major depression disorder (MDD), nicotine dependence, social anxiety disorder, generalized anxiety disorder, or phobias, and subject is not receiving pharmacological treatment for the comorbidity/secondary diagnoses (e.g., antidepressant for MDD) at time of screening nor for the duration of study.
8. Has organic mental disorders, or mental disorders due to a general medical condition (per DSM-5 criteria).
9. Has a current diagnosis or history of substance use disorder including alcohol use disorder (excluding nicotine and caffeine) (per DSM-5 criteria) within the 12 months prior to screening; or is assessed by the Investigator as having regularly consumed alcohol exceeding 21 units for males and 14 units for females per week (1 unit equals 340 mL of beer, 115 mL of wine, or 43 mL of spirits) within the 12 months prior to screening.
10. Is currently using, or has a positive result on the drug screening at the Screening Visit for drugs of abuse (alcohol, opiates, methadone, cocaine, methamphetamine \[including ecstasy\], phencyclidine, propoxyphene, methylphenidate, barbiturates, and benzodiazepines). If subject's serum drug screen for ethanol is positive at screening (Visit 'S') and the investigator determines subject does not have alcohol use disorder, then the subject may have a repeat serum drug screen for ethanol performed before Visit 1 within the allotted screening period (results must be received prior to Visit 1). If second serum drug screen for ethanol is positive, subject is excluded from participating in the study, however, if second serum drug screen for ethanol is negative, subject may proceed to Visit 1.
11. Is a (known or self-identified) current habitual/chronic cannabis user (medicinal or recreational); or
* Has a positive urine drug screen for cannabis at screening (Visit 'S') and is considered, per the Investigator's judgement, to be a habitual/chronic cannabis user; or
* Has a positive urine drug screen for cannabis at both the screening (Visit 'S') and follow-up drug screen (Visit 1), even though the subject is not considered, per the Investigator's judgement, to be a habitual/chronic cannabis user.
Note: Subjects who have a positive urine drug screen for cannabis at screening (Visit 'S') but who are not considered, per the Investigator's judgement, to be a habitual/chronic cannabis user may, with Sponsor approval, undergo an additional urine drug screen at least 4 weeks after the initial urine drug screen at Visit 1 prior to randomization. Subjects must agree to refrain from cannabis use throughout study.
12. Has treatment-resistant ADHD based on a history of receipt of \>2 approved ADHD medications that failed to adequately improve the subject's symptoms, with the exception of subjects who completed Study 812P306. A subject who is naïve to ADHD treatment is not excluded from study participation.
13. Has any other disorder for which its treatment takes priority over treatment of ADHD or is likely to interfere with study treatment, impair treatment compliance, or interfere with interpretation of study results.
14. Has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin that has not been in remission for \> 5 years prior to the first dose of SM.
15. Has or has had one or more of the following conditions considered clinically significant/relevant by the Investigator in the context of the study:
* cardiovascular disease
* congestive heart failure
* cardiac hypertrophy
* arrhythmia
* bradycardia (pulse \< 50 bpm)
* tachycardia (pulse \> 100 bpm)
* respiratory disease
* hepatic impairment or renal insufficiency
* metabolic disorder
* endocrine disorder
* gastrointestinal disorder
* hematological disorder
* infectious disorder
* any clinically significant immunological condition
* dermatological disorder
16. Exhibits clinically significant abnormal vital signs at screening (see Note below).
17. Has one or more screening clinical laboratory test values outside the reference range that, in the opinion of the Investigator, are clinically significant, or any of the following (see Note below):
* Serum creatinine \> 1.5 × the upper limit of normal (ULN);
* Serum total bilirubin \> 1.5 × ULN;
* Serum alanine aminotransferase or aspartate aminotransferase \> 2 × ULN.
18. Has any of the following cardiology findings at screening (see Note below):
* Abnormal ECG that is, in the Investigator's opinion, clinically significant;
* PR interval \> 220 ms;
* QRS interval \> 130 ms;
* QTcF interval \> 450 ms (for men) or \> 470 ms (for women) (QT corrected using Fridericia's method);
* Second- or third-degree atrioventricular block;
* Any rhythm, other than sinus rhythm, that is interpreted by the Investigator to be clinically significant.
19. Has any disease or medication that could, in the Investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with study conduct or interpretation of results.
20. Evidence of infection with hepatitis B or C, or human immunodeficiency virus (HIV)-1 or HIV-2, as determined by results of testing at screening.
21. Lost or donated more than 450 mL of blood during the 30 days prior to screening.
22. Use of any investigational drug or prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) within 30 days or 5 halflives prior to Visit 1 (baseline) (whichever is longer) during the screening period or anticipated for the duration of the study.
23. History of unexplained loss of consciousness, unexplained syncope, unexplained irregular heartbeats or palpitations or near drowning with hospital admission.
24. Has attempted suicide within the 6 months prior to screening, or is at significant risk of suicide, either in the opinion of the Investigator or defined as a "yes" to suicidal ideation questions 4 or 5 or answering "yes" to suicidal behavior on the Columbia- Suicide Severity Rating Scale (C-SSRS) within the 6 months prior to screening.
25. In the Investigator's opinion, is unlikely to comply with the protocol or is unsuitable for any other reason.
2. Has any current psychiatric disorder per Diagnostic and Statistical Manual of Mental Disorders - 5th Edition (DSM-5) criteria other than ADHD with the following exceptions: ADHD is primary diagnosis with comorbidity/secondary diagnoses of major depression disorder (MDD), nicotine dependence, social anxiety disorder, generalized anxiety disorder, or phobias.
3. Current diagnosis of significant systemic disease and/or of a major psychiatric or neurological disorder, including history or family history of seizures or seizure-like disorders.
4. Current evidence of suicidality (suicidal thoughts or behaviors).
5. Female subjects who are pregnant, lactating and/or sexually active and not agreeing to use one of the acceptable birth control methods throughout the study.
6. Has a positive result on urine drug screen at Visit 1.
7. Use of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) at the Visit 1 for the duration of the study.
8. Has a clinical laboratory value, vital sign value or ECG result at Visit 1 that is considered to be clinically significant in the opinion of the Investigator.
9. Has one or more clinical laboratory test values outside the reference range at Visit 1 that, in the opinion of the Investigator, are clinically significant, or any of the following (see Note below):
* Serum creatinine \> 1.5 times the upper limit of normal (ULN);
* Serum total bilirubin \> 1.5 times ULN;
* Serum alanine aminotransferase or aspartate aminotransferase \> 2 times ULN.
10. Has any of the following cardiology findings at Visit 1 (see Note below):
* Abnormal ECG that is, in the Investigator's opinion, clinically significant;
* PR interval \> 220 ms;
* QRS interval \> 130 ms;
* QTcF interval \> 450 ms (for men) or \> 470 ms (for women) (QT corrected using Fridericia's method);
* Second- or third-degree atrioventricular block;
* Any rhythm, other than sinus rhythm, that is interpreted by the Investigator to be clinically significant.
11. Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
1. Is currently participating in another clinical trial or has participated in a clinical trial within 60 days prior screening, with the exception of Study 812P306.
2. Is a member of the study personnel or of their immediate families, or is a subordinate (or immediate family member of a subordinate) to any of the study personnel.
3. Female subjects who are pregnant, lactating and/or sexually active and not agreeing to use one of the acceptable birth control methods throughout the study.
4. Has a history of severe drug allergy or hypersensitivity, or known hypersensitivity, to the study medication.
5. Has a history of moderate or severe head trauma or other neurological disorder or systemic medical disease that, in the Investigator's opinion, is likely to affect central nervous system functioning. This would include subjects with:
1. A current diagnosis of a major neurological disorder; or
2. Seizures, seizure disorder or seizure-like events; or a history of seizure disorder within the immediate family (siblings, parents); or Encephalopathy
6. Has any history of schizophrenia, schizoaffective disorder, bipolar disorder, borderline personality disorder, antisocial personality disorder, narcissistic personality disorder, autism, post-traumatic stress disorder or obsessive-compulsive disorder.
7. Has any current psychiatric disorder (per DSM-5 criteria) other than ADHD with the following exceptions: ADHD is primary diagnoses with comorbidity/secondary diagnoses of major depression disorder (MDD), nicotine dependence, social anxiety disorder, generalized anxiety disorder, or phobias, and subject is not receiving pharmacological treatment for the comorbidity/secondary diagnoses (e.g., antidepressant for MDD) at time of screening nor for the duration of study.
8. Has organic mental disorders, or mental disorders due to a general medical condition (per DSM-5 criteria).
9. Has a current diagnosis or history of substance use disorder including alcohol use disorder (excluding nicotine and caffeine) (per DSM-5 criteria) within the 12 months prior to screening; or is assessed by the Investigator as having regularly consumed alcohol exceeding 21 units for males and 14 units for females per week (1 unit equals 340 mL of beer, 115 mL of wine, or 43 mL of spirits) within the 12 months prior to screening.
10. Is currently using, or has a positive result on the drug screening at the Screening Visit for drugs of abuse (alcohol, opiates, methadone, cocaine, methamphetamine \[including ecstasy\], phencyclidine, propoxyphene, methylphenidate, barbiturates, and benzodiazepines). If subject's serum drug screen for ethanol is positive at screening (Visit 'S') and the investigator determines subject does not have alcohol use disorder, then the subject may have a repeat serum drug screen for ethanol performed before Visit 1 within the allotted screening period (results must be received prior to Visit 1). If second serum drug screen for ethanol is positive, subject is excluded from participating in the study, however, if second serum drug screen for ethanol is negative, subject may proceed to Visit 1.
11. Is a (known or self-identified) current habitual/chronic cannabis user (medicinal or recreational); or
* Has a positive urine drug screen for cannabis at screening (Visit 'S') and is considered, per the Investigator's judgement, to be a habitual/chronic cannabis user; or
* Has a positive urine drug screen for cannabis at both the screening (Visit 'S') and follow-up drug screen (Visit 1), even though the subject is not considered, per the Investigator's judgement, to be a habitual/chronic cannabis user.
Note: Subjects who have a positive urine drug screen for cannabis at screening (Visit 'S') but who are not considered, per the Investigator's judgement, to be a habitual/chronic cannabis user may, with Sponsor approval, undergo an additional urine drug screen at least 4 weeks after the initial urine drug screen at Visit 1 prior to randomization. Subjects must agree to refrain from cannabis use throughout study.
12. Has treatment-resistant ADHD based on a history of receipt of \>2 approved ADHD medications that failed to adequately improve the subject's symptoms, with the exception of subjects who completed Study 812P306. A subject who is naïve to ADHD treatment is not excluded from study participation.
13. Has any other disorder for which its treatment takes priority over treatment of ADHD or is likely to interfere with study treatment, impair treatment compliance, or interfere with interpretation of study results.
14. Has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin that has not been in remission for \> 5 years prior to the first dose of SM.
15. Has or has had one or more of the following conditions considered clinically significant/relevant by the Investigator in the context of the study:
* cardiovascular disease
* congestive heart failure
* cardiac hypertrophy
* arrhythmia
* bradycardia (pulse \< 50 bpm)
* tachycardia (pulse \> 100 bpm)
* respiratory disease
* hepatic impairment or renal insufficiency
* metabolic disorder
* endocrine disorder
* gastrointestinal disorder
* hematological disorder
* infectious disorder
* any clinically significant immunological condition
* dermatological disorder
16. Exhibits clinically significant abnormal vital signs at screening (see Note below).
17. Has one or more screening clinical laboratory test values outside the reference range that, in the opinion of the Investigator, are clinically significant, or any of the following (see Note below):
* Serum creatinine \> 1.5 × the upper limit of normal (ULN);
* Serum total bilirubin \> 1.5 × ULN;
* Serum alanine aminotransferase or aspartate aminotransferase \> 2 × ULN.
18. Has any of the following cardiology findings at screening (see Note below):
* Abnormal ECG that is, in the Investigator's opinion, clinically significant;
* PR interval \> 220 ms;
* QRS interval \> 130 ms;
* QTcF interval \> 450 ms (for men) or \> 470 ms (for women) (QT corrected using Fridericia's method);
* Second- or third-degree atrioventricular block;
* Any rhythm, other than sinus rhythm, that is interpreted by the Investigator to be clinically significant.
19. Has any disease or medication that could, in the Investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with study conduct or interpretation of results.
20. Evidence of infection with hepatitis B or C, or human immunodeficiency virus (HIV)-1 or HIV-2, as determined by results of testing at screening.
21. Lost or donated more than 450 mL of blood during the 30 days prior to screening.
22. Use of any investigational drug or prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) within 30 days or 5 halflives prior to Visit 1 (baseline) (whichever is longer) during the screening period or anticipated for the duration of the study.
23. History of unexplained loss of consciousness, unexplained syncope, unexplained irregular heartbeats or palpitations or near drowning with hospital admission.
24. Has attempted suicide within the 6 months prior to screening, or is at significant risk of suicide, either in the opinion of the Investigator or defined as a "yes" to suicidal ideation questions 4 or 5 or answering "yes" to suicidal behavior on the Columbia- Suicide Severity Rating Scale (C-SSRS) within the 6 months prior to screening.
25. In the Investigator's opinion, is unlikely to comply with the protocol or is unsuitable for any other reason.
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Supernus Pharmaceuticals, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan Rubin, MD
Role: STUDY_DIRECTOR
Chief Medical Officer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
South California Research LLC
Beverly Hills, California, United States
Site Status
Collaborative Neuroscience Network
Garden Grove, California, United States
Site Status
Pharmacology Research Institute
Los Alamitos, California, United States
Site Status
Pharmacology Research Institute
Newport Beach, California, United States
Site Status
Artemis Research Institue for Clinical Research
Riverside, California, United States
Site Status
Artemis Institute for Clinical Research
San Diego, California, United States
Site Status
Artemis Institute for Clinical Rearch
San Marcos, California, United States
Site Status
Collaborative Neuroscience Network LLC
Torrance, California, United States
Site Status
Gulfcoast Research Center
Fort Myers, Florida, United States
Site Status
Research Centers of America
Hollywood, Florida, United States
Site Status
Clinical Neuroscience Solutions, Inc
Jacksonville, Florida, United States
Site Status
Meridien Research
Lakeland, Florida, United States
Site Status
Florida Clinical Research Center, LLC
Maitland, Florida, United States
Site Status
Medical Research Group of Central Florida
Orange City, Florida, United States
Site Status
Clinical Neuroscience Solutions Inc.
Orlando, Florida, United States
Site Status
CNS Healthcare
Orlando, Florida, United States
Site Status
Meridien Research
Tampa, Florida, United States
Site Status
Atlanta Center for Medical Research
Atlanta, Georgia, United States
Site Status
iResearch Atlanta
Decatur, Georgia, United States
Site Status
Psych Atlanta
Marietta, Georgia, United States
Site Status
Psychiatric Associates
Overland Park, Kansas, United States
Site Status
St. Charles Psychiatric Associates Midwest Research Center
Saint Charles, Missouri, United States
Site Status
Alivation Research, LLC
Lincoln, Nebraska, United States
Site Status
Altea Research Institute
Las Vegas, Nevada, United States
Site Status
Center for Psychiatry and Behavioral Medicine, Inc.
Las Vegas, Nevada, United States
Site Status
Hassman Research Institute
Berlin, New Jersey, United States
Site Status
Center for Emotional Fitness
Cherry Hill, New Jersey, United States
Site Status
Hassmann Research Institute
Marlton, New Jersey, United States
Site Status
Princeton Medical Institute
Princeton, New Jersey, United States
Site Status
Bioscience Research
Mount Kisco, New York, United States
Site Status
The Medical Research Network LLC
New York, New York, United States
Site Status
Paradigm Research Professionals
Oklahoma City, Oklahoma, United States
Site Status
Clinical Neuroscience Solutions
Memphis, Tennessee, United States
Site Status
BioBehavioral Research of Austin P.C.
Austin, Texas, United States
Site Status
FutureSearch Trials of Dallas, LLP
Dallas, Texas, United States
Site Status
Houston Clinical Trials
Houston, Texas, United States
Site Status
Family Psychiatry of the Woodlands
The Woodlands, Texas, United States
Site Status
Northwest Clinical Trials
Bellevue, Washington, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Childress A, Cutler AJ, Adler LA, Fry N, Asubonteng K, Maldonado-Cruz Z, Formella A, Rubin J. An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 2024 Nov;38(11):891-907. doi: 10.1007/s40263-024-01120-0. Epub 2024 Oct 7.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
812P311
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
NCT02633527
COMPLETED
PHASE2
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
NCT03247543
COMPLETED
PHASE3
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
NCT03247556
COMPLETED
PHASE3
Classroom Study of SPN-812 in Children With ADHD
NCT04016792
WITHDRAWN
PHASE3
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
NCT04786990
COMPLETED
PHASE4
Evaluation of Immediate-Release Viloxazine in Adults With ADHD
NCT01107496
COMPLETED
PHASE1/PHASE2
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
NCT00626236
COMPLETED
PHASE2
Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)
NCT02253745
COMPLETED
PHASE1/PHASE2
Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M
NCT02023606
COMPLETED
PHASE1
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00307684
COMPLETED
PHASE3
A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT01364662
COMPLETED
PHASE2
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD
NCT02168127
COMPLETED
PHASE3
A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.
NCT00566449
COMPLETED
PHASE2
Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder
NCT00877487
COMPLETED
PHASE4
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
NCT01338818
COMPLETED
PHASE3
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
NCT01074294
COMPLETED
PHASE2
A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.
NCT00246220
COMPLETED
PHASE3
Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder
NCT00467428
COMPLETED
PHASE2
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
NCT03460652
COMPLETED
PHASE3
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
NCT01259492
COMPLETED
PHASE3
Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults
NCT00048360
COMPLETED
PHASE3
Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder
NCT00269815
COMPLETED
PHASE3
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
NCT00334880
COMPLETED
PHASE3